Low dose pegylated recombinant human granulocyte colony-stimulating factor in the prophylactic treatment of grade Ⅲ/Ⅳ myelosuppression after chemotherapy
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 10
Abstract
"Objective To investigate the impact of low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on grade Ⅲ/Ⅳ myelosuppression following chemotherapy. Methods A total of 80 patients with malignant tumors admitted to the First Affiliated Hospital of Anhui University of Science and Technology from April 2022 to September 2023 were selected as research subjects. The patients were randomly divided into the control group (n=40) and the observation group (n=40). The observation group and the control group received subcutaneous injections of 3.0 mg and 6.0 mg PEG-rhG-CSF, respectively, within 24 to 48 hours after chemotherapy. The incidence and duration of grade Ⅲ/Ⅳ neutropenia, febrile neutropenia (FN), adverse reactions, as well as changes in quality of life ［European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)］ scores before and after treatment were observed in both groups after medication. Results After medication, there was no significant difference in the incidence of grade Ⅲ/Ⅳ neutropenia or FN between the two groups (P＞0.05). The observation group exhibited higher levels for neutrophils compared to control group ［(1.77±0.70)×109/L vs (1.50±0.41)×109/L, t=2.071, P=0.042］. Grade Ⅲ/Ⅳ neutropenia occurred in 1 case in the control group, which lasted for 1 day, while 3 cases occurred in the observation group, which lasted for 2-4 days. Compared with the control group, the occurrence rate of adverse reactions was lower in the observation group (72.50% vs 90.00%, χ<sup>2</sup>=4.021, P=0.045), and EORTC QLQ-C30 were higher for patients in the observation group (P＜0.05). Conclusion Low-dose PEG-rhG-CSF demonstrates similar efficacy rates as standard doses for prophylactic managing gradeⅢ/Ⅳ myelosuppression following chemotherapy, but it exhibits a lower incidence rate of adverse reactions and improves quality-of-life of patients."
Authors and Affiliations
WANG Jin, TIE Xiaowei, FU Baobao, JIA Qianqian, WANG Fang, LI Wei
Keywords
Related Articles
- EP ID EP749061
- DOI -
- Views 28
- Downloads 0
Predictive value of serum actinin-4, TFF1, and TGFBI for the prognosis of patients with primary hepatocellular carcinoma after transarterial chemoembolization
Objective To investigate the predictive value of serum actinin-4, trefoil factor 1 (TFF1), and transforming growth factor-β-induced protein (TGFBI) for the prognosis of patients with primary hepatocellular carcinoma (PHC...
Research progress of fibroblast growth factor receptor in gastric cancer
The incidence and mortality of gastric cancer are in the forefront of the tumor, and the prognosis is poor, especially in the middle and advanced stage. Even with comprehensive treatment, the 5- year survival is very lo...
Preoperative controlling nutritional status on the prognosis of postoperative gastric cancer patients： a Meta-analysis
<b>Objective</b> To evaluate the prognostic value of controlling nutritional status score (CONUT) in patients undergoing gastrectomy for gastric cancer. <b>Methods</b> CNKI, Wanfang, China Biomedical Literature Library,...
Application of intelligent nursing service mode based on the Internet in patients with enterostomy
Objective To explore the application effect of an Internet-based intelligent nursing service model in the care of patients with enterostomy. Methods A total of 100 patients with enterostomy in the People's Hospital of Xi...
Clinical efficacy of robotic pancreaticoduodenectomy in treatment of periampullary carcinoma
"<b>Objective</b> To investigate the clinical application and efficacy of Da Vinci robotic assisted pancreaticoduodenectomy (RPD) in treatment of periampullary carcinoma（PAC）. <b>Methods</b> The clinical data of 8...